LAG3抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human ovarian cancer tissue, Primary antibody: P10990(LAG3 Antibody) at dilution 1/148, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

LAG3 (Lymphocyte-Activation Gene 3), a cell surface protein belonging to the immunoglobulin superfamily, functions as an immune checkpoint receptor that negatively regulates T-cell activation and homeostasis. Primarily expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells, LAG3 interacts with MHC class II molecules and other ligands, such as fibrinogen-like protein 1 (FGL1), to suppress effector T-cell proliferation, cytokine secretion, and cytotoxicity. This inhibitory mechanism helps maintain immune tolerance but is often exploited by tumors to evade immune surveillance.

Research over the past decade has highlighted LAG3 as a promising therapeutic target, particularly in combination with other checkpoint inhibitors like PD-1/PD-L1 blockers. Preclinical studies demonstrated that LAG3 blockade rejuvenates exhausted T cells and synergizes with anti-PD-1 therapies to enhance antitumor responses. In 2022. the FDA approved relatlimab (a LAG3 inhibitor) combined with nivolumab (anti-PD-1) for advanced melanoma, marking the first LAG3-targeted therapy to reach clinical use.

Ongoing trials explore LAG3 antibodies in diverse cancers, including lymphoma, lung, and colorectal cancer. Challenges remain in optimizing dosing, understanding resistance mechanisms, and identifying predictive biomarkers. Despite these hurdles, LAG3 inhibition represents a critical advancement in cancer immunotherapy, expanding treatment options beyond traditional checkpoint targets.